



KOL Dinner at ASH 2016 & Cocktail Reception

LifeSci Capital is hosting a Key Opinion Leader (KOL) dinner with hematologist Dr. Louis Aledort (Mt. Sinai) and oncologist Dr. William Matsui (Johns Hopkins) at the American Society of Hematology's Annual Meeting in San Diego, CA on Sunday, December 4, 2016.

Please join us after dinner for cocktails in San Diego's Gaslamp Quarter.

Sunday,
December 4, 2016

KOL Dinner: 7:00 pm
Cocktail Reception: 9:00 pm

Location: San Diego, CA Restaurant TBA

To RSVP for the KOL Dinner **AND** Cocktail Reception, please click on the button below:

KOL & Cocktails

To RSVP for the Cocktail Reception **ONLY**, please click on the button below:



















Cocktails Only

The KOL Dinner will feature a discussion on abstracts and updates presented at the conference and will include the following topics:

- New Hemophilia treatment data (Spark Therapeutics)
- CAR-T therapy updates (KITE, JUNO, BLUE, NVS, etc)
- Developments in the treatment landscape for leukemias and multiple myeloma



Anticipated Companies Affected

 Ticker: KITE	 Ticker: ONCE	 Ticker: JUNO	 Ticker: BMRN
 Ticker: CBIO	 Ticker: BLUE	 Ticker: CELG	 Ticker: TRIL
 Ticker: CLLS	 Ticker: AGIO	 Ticker: NVS	 Ticker: QURE
 Ticker: JAZZ	 Private	 Ticker: SGMO	 Ticker: ROG.VX
 Ticker: BLCM	 Ticker: SNSS		

KOL Biographies

Louis M. Aledort, MD, MACP

Louis M. Aledort, MD, MACP is a Professor of Medicine in the Department of Hematology and Medical Oncology at Mount Sinai School of Medicine in New York. He is also the Mary Weinfeld Professor of Clinical Research in Hemophilia at Mt. Sinai. Dr. Aledort's research interests are in clotting disorders, bleeding problems, von Willebrand's disease, hemophilia, thrombosis, platelet disorders, and vasculitis. In his over 40 years in medicine, Dr. Aledort has published numerous papers and clinical trials. He has served as consultant to the World Health Organization, Pan American Health Organization, and the House Ways & Means Committee. Dr. Aledort has chaired and been a member of the practice committees of the American Society of Hematology and American College of Physicians. He has written more than 300 articles on several aspects of bleeding and clotting disorders.

William H. Matsui, MD

William H. Matsui, MD is a Professor of Oncology at the Johns Hopkins University School of Medicine within the Division of Hematologic Malignancies. He directs the Multiple Myeloma Program at the Johns Hopkins Kimmel Cancer Center. The primary focus of Dr. Matsui's research is to better understand the role of cancer stem cells in hematologic malignancies and develop novel therapeutic strategies to target these cells. Dr. Matsui and his team have identified several novel therapeutic strategies to target cancer stem cells including the Hedgehog signaling pathway, focal adhesion kinase, and telomerase. Many of these basic findings have served as the foundation for preclinical studies and clinical trials. He has published over a hundred scientific articles in major journals within the fields of hematology and oncology, and has been recognized by the Leukemia and Lymphoma Society, the American Society of Clinical Oncology, and the American Society of Clinical Investigation for his scholarly achievements.